Using stock price movements to estimate the harm from collusive drug patent litigation settlements
{{output}}
The tradeoff between incentives to invest in R&D and efficient pricing takes a special form in the pharmaceutical sector. Brand drugs command high prices until generic competition begins, the timing of which usually depends on the outcome of patent infringemen... ...
